secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0000950170-25-069183
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenon Q1 net loss $65.0M; X-TOLE2 topline data shifted to early 2026
--------------------------------------------------------------------

- Net loss of $65.0M (vs $47.9M Q1 2024) on higher R&D spend of $61.2M; revenue $7.5M from Neurocrine milestone.
- Cash and securities $691.1M (down from $754.4M Dec 2024); cash runway into 2027.
- Phase 3 X-TOLE2 FOS study recruitment to complete in months; topline data now expected early 2026 (modest shift).
- Phase 3 MDD (X-NOVA3) and bipolar depression studies on track to initiate mid-2025.
- Phase 1 started for XEN1120 (Kv7); IND for XEN1701 (Nav1.7) expected Q3 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000095017025069183/0000950170-25-069183-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000095017025069183/xene-20250512.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-069183

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer